Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

0.9329 +0.1629 (+21.16%)
Streaming Delayed Price Updated: 1:32 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tiziana Life Sciences Ltd - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
7 Battered Blue-Chip Stocks to Bounce From Your Portfolio This Spring ↗
Not all big companies are doing well in the stock market. For various reasons, these battered blue-chip stocks are struggling mightily. 
Via InvestorPlace
News headline image
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans 
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
3 EV Stocks to Buy on the Dip: March 2024 ↗
The electric vehicle market slump has significantly impacted many EV stocks to buy - But the slump will not last forever. 
Via InvestorPlace
Topics Electric Vehicles
News headline image
3 EV Stocks to Buy for the Next Bull Run: March 2024 ↗
EV stocks have broadly underperformed the market in 2024, which has, in turn, created a number of opportunities to buy at a bargain. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
7 Over-Hyped Stocks to Sell Before They Plunge ↗
It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell. 
Via InvestorPlace
News headline image
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says ↗
Tesla shares fell only slightly. And auto recalls are nothing new. Recall how, in 1981, Ford issued a recall on 21 million vehicles. 
Via Benzinga
Topics Product Recall
News headline image
Don't Get Caught In Equity Rally Hype: Lessons From 2023 To Remember In 2024 ↗
After a volatile 2023, equity markets appear to be rallying into 2024. Can they keep it up? 
Via Benzinga
News headline image
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab
--News Direct-- 
Via News Direct
News headline image
Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab ↗
This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS)... 
Via Benzinga
News headline image
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
SPDR ETF Report For Tuesday, November 21 ↗
Via Talk Markets
Topics ETFs
News headline image
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! 
Via InvestorPlace
News headline image
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
--News Direct-- 
Via News Direct
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
Tiziana Life Sciences reports six-month PET scan results for MS patients
--News Direct-- 
Via News Direct
Tiziana Life Sciences reports six-month PET scan results for MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.